• KANIKA KHAJURIA Department of Pharmacology, ASCOMS, Sidhra, UT Jammu and Kashmir 180017
  • VIJAY KHAJURIA Department of Pharmacology, Government Medical College Kathua (UT Jammu and Kashmir) 184101
  • VINEETA SAWHNEY Department of Pharmacology, Government Medical College Kathua (UT Jammu and Kashmir) 184101


Mitochondria are the most vital organelle in the cell because of its multitask properties. They are well known for the production of energy in the form of adenosine triphosphate (ATP) through oxidative phosphorylation (OXPHOS), which involves multiple complexes and cofactors. Mitochondria in addition to ATP production, also perform other vital functions like generation of reactive oxygen species (ROS), antioxidants, apoptosis, signaling and hormone actions.

Because of their multiple actions, it is quite expected that their dysfunction will result in the number of effects. Since most vital organs exclusively depend on ATP to perform their functions, therefore impediment in its supply resulting from mitochondrial dysfunction will be detrimental and have a widespread spectrum. Neurodegenerative disorders, Huntington’s disease, cardiovascular disease (CVD), epilepsy, aging, metabolic syndrome, diabetes, autism, muscular atrophy, lou gehrig’s disease, neoplasia, down syndrome are few instances where mitochondrial dysfunction is the basic cause in pathogenesis.

Mitochondrial disorders are either Primary or secondary disorders. Primary mitochondrial disease or disorder (PMD) has mitochondrial or nuclear deoxyribonucleic acid (mt DNA or nDNA) mutation affecting oxidative phosphorylation (OXPHOS). While Secondary mitochondrial dysfunction (SMD) does not involve OXPHOS but is the result of mutations in non OXPHOS genes. Secondary mitochondrial dysfunction (SMD) can also be acquired secondary to adverse factors those cause oxidative stress.

All this highlights the role of mitochondria and makes it a new therapeutic target in managing these disorders. The present review has briefly discussed the secondary mitochondrial dysfunctional disorders and the approach to tackle it.

Keywords: Mitochondrial dysfunction, OXPHOS, ATP, Secondary mitochondrial dysfunction


Download data is not yet available.


1. Chinnery PF. Mitochondrial disorders overview. Gene Reviews. Available from: [Last update on 14 Aug 2014]
2. Psarra MG, Solakidi S, Sekeris CE. The mitochondrion as a primary site of action of steroid and thyroid hormones: presence and action of steroid and thyroid hormone receptors in mitochondria of animal cells. Mol Cell Endocrinol 2006;246:21-33.
3. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009;361:1570–83.
4. Siasos G, Tsigkou V, Kosmopoulos M, Theodosiadis D, Simantiris S, Tagkou NM, et al. Mitochondria and cardiovascular diseases from pathophysiology to treatment. Ann Transl Med 2018;6:256.
5. Scialo F , Fernandez Ayala DJ, Sanz A. Role of mitochondrial reverse electron transport in ROS signaling: potential roles in health and disease. Front Physiol 2017;8:428.
6. Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 2007;47:143–83.
7. Rachek LI, Yuzefovych LV, Ledoux SP, Julie NL, Wilson GL. Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol Appl Pharmacol 2009;240:348–54.
8. Logan AC, Wong C. Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern Med Rev 2001;6:450–9.
9. Keenoy BMY, Moorkens G, Vertommen J, De Leeuw I. Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci 2001;68:2037–49.
10. Pall ML. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med Hypotheses 2000;54:115–25.
11. Zhang H, Feng Y, Yao Y. Potential therapy strategy: targeting mitochondrial dysfunction in sepsis. Military Med Res 2018;5:41.
12. Sireesha K, Rao PA. Oxidative stress and diabetes: an overview. Asian J Pharm Clin Res 2015;8:15-9.
13. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence 2014;5:66–72.
14. Jia G, Aroor AR, Sowers JR. Estrogen and mitochondria function in cardiorenal metabolic syndrome. Prog Mol Biol Transl Sci 2014;127:229-49.
15. Antoniades C, Tousoulis D, Marinou K, Papageorgiou N, Bosinakou E, Tsioufis C, et al. Effects of insulin dependence on the inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis. Clin Cardiol 2007;30:295-300.
16. Jelenik T, Roden M. Mitochondrial plasticity in obesity and diabetes mellitus. Antioxid Redox Signal 2013;19:258-68.
17. Montgomery MK, Turner N. Mitochondrial dysfunction and insulin resistance: an update. Endocr Connect 2015;4:R1-15.
18. Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 2010;31:364-95.
19. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radical Biol Med 2011;50:567-75.
20. Watanabe T, Saotome M, Nobuhara M. Roles of mitochondrial fragmentation and reactive oxygen species in mitochondrial dysfunction and myocardial insulin resistance. Exp Cell Res 2014;323:314-25.
21. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta 2011;1813:1269-78.
22. Hicks S, Labinskyy N, Piteo B. Type II diabetes increases mitochondrial DNA mutations in the left ventricle of the Goto-Kakizaki diabetic rat. Am J Physiol Heart Circ Physiol 2013;304:H903-15.
23. Sharma V. Alzheimer’s disease: a consequence of impaired mitophagy? Asian J Pharm Clin Res 2019;12:75-80.
24. Park JS, Davis RL, SueCM. Mitochondrial dysfunction in parkinson’s disease: new mechanistic insights and therapeutic perspectives. Curr Neurol Neurosci Rep 2018;18:21.
25. Jha SK, Kumar P. An in silico study of naringenin-mediated neuroprotection in Parkinson's disease Asian J Pharm Clin Res 2017;8:171-6.
26. Wetzel EB, Petrilli A, Knott AB. Mutant huntingtin and mitochondrial dysfunction.Trends Neurosci 2008;31:609–16.
27. Jiang Z, Wang W, Perry G, Zhu X, Wang X. Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis. Transl Neurodegener 2015;4:14.
28. Peoples JN, Saraf A, Ghazal N, Pham TT, Kwong JQ. Mitochondrial dysfunction and oxidative stress in heart disease. Exp Mol Med 2019;51:1–13.
29. Burgoyne JR, Mongue Din H, Eaton P, Shah AM. Redox signaling in cardiac physiology and pathology. Circ Res 2012;111:1091–106.
30. Hall CJ, Sanderson LE, Crosier KE. Mitochondrial metabolism, reactive oxygen species, and macrophage function-fishing for insights. J Mol Med (Berl) 2014;92:1119-28.
31. Pillai VB, Bindu S, Sharp W. Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. Am J Physiol Heart Circ Physiol 2016;310:H962-72.
32. Wu SP, Kao CY, Wang L. Increased COUP-TFII expression in adult hearts induces mitochondrial dysfunction resulting in heart failure. Nat Commun 2015;6:8245.
33. Jian B, Yang S, Chen D. Aging influences cardiac mitochondrial gene expression and cardiovascular function following hemorrhage injury. Mol Med 2011;17:542-9.
34. Dai DF, Johnson SC, Villarin JJ. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and galphaq overexpression-induced heart failure. Circ Res 2011;108:837-46.
35. Sabri A, Hughie HH, Lucchesi PA. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 2003;5:731-40.
36. Costa RM, Filgueira FP, Tostes RC. H2O2 generated from mitochondrial electron transport chain in thoracic perivascular adipose tissue is crucial for modulation of vascular smooth muscle contraction. Vascul Pharmacol 2016;84:28-37.
37. Freed JK, Durand MJ, Hoffmann BR. Mitochondria-regulated formation of endothelium-derived extracellular vesicles shifts the mediator of flow-induced vasodilation. Am J Physiol Heart Circ Physiol 2017;312:H1096-104.
38. Kartika Y, Bangun H, Rosidah R. Effect of sodium alginate on prevention of hypercholesterolemia and atherosclerosis in rats. Asian J Pharm Clin Res 2018;11:242-7.
39. Panth N, Paudel KR, Parajuli K. Reactive oxygen species: a key hallmark of cardiovascular disease. Adv Med 2016; 2016:9152732.
40. Kurz DJ, Decary S, Hong Y. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci 2004;117:2417-26.
41. Stefanadi E, Tousoulis D, Androulakis ES. Inflammatory markers in essential hypertension: potential clinical implications. Curr Vasc Pharmacol 2010;8:509-16.
42. Capettini LS, Montecucco F, Mach F. Role of the renin-angiotensin system in inflammation, immunity and aging. Curr Pharm Des 2012;18:963-70.
43. Chen XH, Zhao YP, Xue M. TNF-alpha induces mitochondrial dysfunction in 3T3-L1 adipocytes. Mol Cell Endocrinol 2010;328:63-9.
44. Osman C, Voelker DR, Langer T. Making heads or tails of phospholipids in mitochondria. J Cell Biol 2011;192:7-16.
45. Vaziri ND. Csausal link between oxidative stress, inflammation, and hypertension. Iran J Kidney Dis 2008;2:1-10.
46. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
47. George P. p53 how crucial is its role in cancer? Int Jout Curr Pharma Res 2011;3:19-25.
48. Mollo N, Cicatiello R, Aurilia M, Scognamiglio R, Genesio R, Charalambous M, et al. Targeting mitochondrial network architecture in down syndrome and aging. Int J Mol Sci 2020;21:31-4.
49. Siddiqui MF, Elwell C, Johnson MH. Mitochondrial dysfunction in autism spectrum disorders. Autism Open Access 2016;6:1000-190.
50. Zsurka G, Kunz WS. Mitochondrial dysfunction and seizures: the neuronal energy crisis. Lancet Neurol 2015;14:956-66.
51. Folbergrova J, Kunz WS. Mitochondrial dysfunction in epilepsy mitochondrion; 2012. p. 35-40.
52. Jang YC, Lustgarten MS, Liu Y, Muller FL, Bhattacharya A, Liang, et al. Increased superoxide in vivo accelerates age-associated muscle atrophy through mitochondrial dysfunction and neuromuscular junction degeneration. FASEB J 2010;24:1376–90.
53. Hyatt H, Deminice R, Yoshihara T, Powers SK. Mitochondrial dysfunction induces muscle atrophy during prolonged inactivity: a review of the causes and effects. Arch Biochem Biophys 2019;662:49-60.
54. Thaler R, Karlic H, Rust P, Haslberger AG. Epigenetic regulation of human buccal mucosa mitochondrial superoxide dismutase gene expression by diet. Br J Nutr 2009;101:743–9.
55. Roberts CK, Won D, Pruthi S. Effect of a diet and exercise intervention on oxidative stress, inflammation and monocyte adhesion in diabetic men. Diabetes Res Clin Pract 2006;73:249-59.
56. Cloonan SM, Choi AM. Mitochondria: commanders of innate immunity and disease? Curr Opin Immunol 2012;24:32–40.
42 Views | 23 Downloads
How to Cite
KHAJURIA, K., V. KHAJURIA, and V. SAWHNEY. “SECONDARY MITOCHONDRIAL DYSFUNCTION”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 13, no. 3, Feb. 2021, pp. 14-19, doi:10.22159/ijpps.2021v13i3.40335.
Review Article(s)